Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
103Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.12M | $-11.17M | $-0.32 |
| 2024 | $43.0K | $-8.81M | $-0.37 |
| 2023 | $0.00 | $-10.23M | $-0.50 |
| 2022 | $0.00 | $-9.89M | $-0.54 |
| 2021 | $0.00 | $-6.32M | $-0.40 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.08 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.05 vs $-0.07beat
- Thu, May 14$-0.08 vs $-0.08beat
- Mon, Mar 30$-0.08 vs $-0.08beat
- Thu, Nov 13$-0.08 vs $-0.08beat
- Thu, Aug 14$-0.08 vs $-0.08beat
- Thu, May 15$-0.08 vs $-0.08beat
Estimates and results for RNXT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
RNXThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsmarketbeat.com·2d ago·Neutral
RenovoRx Q2 Earnings Call Highlights RenovoRx NASDAQ: RNXT reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer.
View source ↗ - Newszacks.com·2d ago·Neutral
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago.
View source ↗